GPP
RXDX

Great Point Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Great Point Partners’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-250,000
Closed -$4.57M – 39
2021
Q1 		$4.57M Buy
+250,000
New +$5.16M 0.94% 24

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Great Point Partners's RXDX Position: Q2 2021 in Review

Great Point Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2021, closing a stake of 250,000 shares — an estimated $4.57M sold.

Great Point Partners first reported a position in RXDX in Q1 2021 and held it in 1 quarter. The position peaked at $4.57M in Q1 2021. 49 funds tracked by Wall St. Rank hold RXDX as of Q2 2021.

  • Great Point Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Great Point Partners sold 250,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $4.57M.
  • Great Point Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Great Point Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $4.57M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2021.

Based on Great Point Partners's 13F filing for Q2 2021, filed 16 Aug 2021.